ArticleClinical epigenetics2016
Article in Clinical epigenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.Cancer biomarkers : section A of Disease markers · 2017Pooled it
- Article
- A novel three-CpG signature for lung adenocarcinoma diagnosis: integrating multi-omics, machine learning, and clinical validation.Translational cancer research · 2026Article
- Hypoxia Associated Integration of Epigenetic, Metabolic, and Immune Biomarkers in Blood and Urine for Early Colorectal Cancer Detection: A Multimarker Panel.Diagnostics (Basel, Switzerland) · 2026Article
- Discovery and characterization of Christensenella hongkongensis as a novel bacterium in the adenoma-carcinoma progression.Journal of translational medicine · 2026Article
- Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Dynamic DNA methylation changes during colorectal oncogenesis with insights from adenoma stages.Scientific reports · 2025Article
- Diagnostic and prognostic value of polygene methylation detection in ascites.Frontiers in genetics · 2025Article
- Genome wide identification of novel DNA methylation driven prognostic markers in colorectal cancer.Scientific reports · 2024Article
- Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer.Scientific reports · 2024Article
- Evaluation of DNA methylation levels ofOncology reports · 2024Article
- Novel DNA methylation biomarkers in stool and blood for early detection of colorectal cancer and precancerous lesions.Clinical epigenetics · 2023Article
- Review
- Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Genome-wide DNA methylation profiling and identification of potential pan-cancer and tumor-specific biomarkers.Molecular oncology · 2022Article
- Down-regulation of lncRNA LUADT1 suppresses cervical cancer cell growth by sequestering microRNA-1207-5p.Acta biochimica et biophysica Sinica · 2022Article
- Epigenome-Wide DNA Methylation Profiling in Colorectal Cancer and Normal Adjacent Colon Using Infinium Human Methylation 450K.Diagnostics (Basel, Switzerland) · 2022Article
- A detection panel of novel methylated DNA markers for malignant pleural effusion.Frontiers in oncology · 2022Article
- A functional methylation signature to predict the prognosis of Chinese lung adenocarcinoma based on TCGA.Cancer medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) appear to arise from precursor lesions in a well-characterized adenoma-carcinoma sequence. Significant efforts have been invested to develop biomarkers that identify early adenocarcinomas and adenomas with high-grade dysplasia, since these are believed to harbor a particularly high risk for malignant transition and thus require resection. Promoter methylation of
resultsAssessment of promoter methylation of
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.